Cargando…

Clinical Effects and Antivenom Dosing in Brown Snake (Pseudonaja spp.) Envenoming — Australian Snakebite Project (ASP-14)

BACKGROUND: Snakebite is a global health issue and treatment with antivenom continues to be problematic. Brown snakes (genus Pseudonaja) are the most medically important group of Australian snakes and there is controversy over the dose of brown snake antivenom. We aimed to investigate the clinical a...

Descripción completa

Detalles Bibliográficos
Autores principales: Allen, George E., Brown, Simon G. A., Buckley, Nicholas A., O’Leary, Margaret A., Page, Colin B., Currie, Bart J., White, Julian, Isbister, Geoffrey K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3532501/
https://www.ncbi.nlm.nih.gov/pubmed/23300888
http://dx.doi.org/10.1371/journal.pone.0053188
_version_ 1782254320499032064
author Allen, George E.
Brown, Simon G. A.
Buckley, Nicholas A.
O’Leary, Margaret A.
Page, Colin B.
Currie, Bart J.
White, Julian
Isbister, Geoffrey K.
author_facet Allen, George E.
Brown, Simon G. A.
Buckley, Nicholas A.
O’Leary, Margaret A.
Page, Colin B.
Currie, Bart J.
White, Julian
Isbister, Geoffrey K.
author_sort Allen, George E.
collection PubMed
description BACKGROUND: Snakebite is a global health issue and treatment with antivenom continues to be problematic. Brown snakes (genus Pseudonaja) are the most medically important group of Australian snakes and there is controversy over the dose of brown snake antivenom. We aimed to investigate the clinical and laboratory features of definite brown snake (Pseudonaja spp.) envenoming, and determine the dose of antivenom required. METHODS AND FINDING: This was a prospective observational study of definite brown snake envenoming from the Australian Snakebite Project (ASP) based on snake identification or specific enzyme immunoassay for Pseudonaja venom. From January 2004 to January 2012 there were 149 definite brown snake bites [median age 42y (2–81y); 100 males]. Systemic envenoming occurred in 136 (88%) cases. All envenomed patients developed venom induced consumption coagulopathy (VICC), with complete VICC in 109 (80%) and partial VICC in 27 (20%). Systemic symptoms occurred in 61 (45%) and mild neurotoxicity in 2 (1%). Myotoxicity did not occur. Severe envenoming occurred in 51 patients (38%) and was characterised by collapse or hypotension (37), thrombotic microangiopathy (15), major haemorrhage (5), cardiac arrest (7) and death (6). The median peak venom concentration in 118 envenomed patients was 1.6 ng/mL (Range: 0.15–210 ng/mL). The median initial antivenom dose was 2 vials (Range: 1–40) in 128 patients receiving antivenom. There was no difference in INR recovery or clinical outcome between patients receiving one or more than one vial of antivenom. Free venom was not detected in 112/115 patients post-antivenom with only low concentrations (0.4 to 0.9 ng/ml) in three patients. CONCLUSIONS: Envenoming by brown snakes causes VICC and over a third of patients had serious complications including major haemorrhage, collapse and microangiopathy. The results of this study support accumulating evidence that giving more than one vial of antivenom is unnecessary in brown snake envenoming.
format Online
Article
Text
id pubmed-3532501
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-35325012013-01-08 Clinical Effects and Antivenom Dosing in Brown Snake (Pseudonaja spp.) Envenoming — Australian Snakebite Project (ASP-14) Allen, George E. Brown, Simon G. A. Buckley, Nicholas A. O’Leary, Margaret A. Page, Colin B. Currie, Bart J. White, Julian Isbister, Geoffrey K. PLoS One Research Article BACKGROUND: Snakebite is a global health issue and treatment with antivenom continues to be problematic. Brown snakes (genus Pseudonaja) are the most medically important group of Australian snakes and there is controversy over the dose of brown snake antivenom. We aimed to investigate the clinical and laboratory features of definite brown snake (Pseudonaja spp.) envenoming, and determine the dose of antivenom required. METHODS AND FINDING: This was a prospective observational study of definite brown snake envenoming from the Australian Snakebite Project (ASP) based on snake identification or specific enzyme immunoassay for Pseudonaja venom. From January 2004 to January 2012 there were 149 definite brown snake bites [median age 42y (2–81y); 100 males]. Systemic envenoming occurred in 136 (88%) cases. All envenomed patients developed venom induced consumption coagulopathy (VICC), with complete VICC in 109 (80%) and partial VICC in 27 (20%). Systemic symptoms occurred in 61 (45%) and mild neurotoxicity in 2 (1%). Myotoxicity did not occur. Severe envenoming occurred in 51 patients (38%) and was characterised by collapse or hypotension (37), thrombotic microangiopathy (15), major haemorrhage (5), cardiac arrest (7) and death (6). The median peak venom concentration in 118 envenomed patients was 1.6 ng/mL (Range: 0.15–210 ng/mL). The median initial antivenom dose was 2 vials (Range: 1–40) in 128 patients receiving antivenom. There was no difference in INR recovery or clinical outcome between patients receiving one or more than one vial of antivenom. Free venom was not detected in 112/115 patients post-antivenom with only low concentrations (0.4 to 0.9 ng/ml) in three patients. CONCLUSIONS: Envenoming by brown snakes causes VICC and over a third of patients had serious complications including major haemorrhage, collapse and microangiopathy. The results of this study support accumulating evidence that giving more than one vial of antivenom is unnecessary in brown snake envenoming. Public Library of Science 2012-12-28 /pmc/articles/PMC3532501/ /pubmed/23300888 http://dx.doi.org/10.1371/journal.pone.0053188 Text en © 2012 Allen et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Allen, George E.
Brown, Simon G. A.
Buckley, Nicholas A.
O’Leary, Margaret A.
Page, Colin B.
Currie, Bart J.
White, Julian
Isbister, Geoffrey K.
Clinical Effects and Antivenom Dosing in Brown Snake (Pseudonaja spp.) Envenoming — Australian Snakebite Project (ASP-14)
title Clinical Effects and Antivenom Dosing in Brown Snake (Pseudonaja spp.) Envenoming — Australian Snakebite Project (ASP-14)
title_full Clinical Effects and Antivenom Dosing in Brown Snake (Pseudonaja spp.) Envenoming — Australian Snakebite Project (ASP-14)
title_fullStr Clinical Effects and Antivenom Dosing in Brown Snake (Pseudonaja spp.) Envenoming — Australian Snakebite Project (ASP-14)
title_full_unstemmed Clinical Effects and Antivenom Dosing in Brown Snake (Pseudonaja spp.) Envenoming — Australian Snakebite Project (ASP-14)
title_short Clinical Effects and Antivenom Dosing in Brown Snake (Pseudonaja spp.) Envenoming — Australian Snakebite Project (ASP-14)
title_sort clinical effects and antivenom dosing in brown snake (pseudonaja spp.) envenoming — australian snakebite project (asp-14)
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3532501/
https://www.ncbi.nlm.nih.gov/pubmed/23300888
http://dx.doi.org/10.1371/journal.pone.0053188
work_keys_str_mv AT allengeorgee clinicaleffectsandantivenomdosinginbrownsnakepseudonajasppenvenomingaustraliansnakebiteprojectasp14
AT brownsimonga clinicaleffectsandantivenomdosinginbrownsnakepseudonajasppenvenomingaustraliansnakebiteprojectasp14
AT buckleynicholasa clinicaleffectsandantivenomdosinginbrownsnakepseudonajasppenvenomingaustraliansnakebiteprojectasp14
AT olearymargareta clinicaleffectsandantivenomdosinginbrownsnakepseudonajasppenvenomingaustraliansnakebiteprojectasp14
AT pagecolinb clinicaleffectsandantivenomdosinginbrownsnakepseudonajasppenvenomingaustraliansnakebiteprojectasp14
AT curriebartj clinicaleffectsandantivenomdosinginbrownsnakepseudonajasppenvenomingaustraliansnakebiteprojectasp14
AT whitejulian clinicaleffectsandantivenomdosinginbrownsnakepseudonajasppenvenomingaustraliansnakebiteprojectasp14
AT isbistergeoffreyk clinicaleffectsandantivenomdosinginbrownsnakepseudonajasppenvenomingaustraliansnakebiteprojectasp14
AT clinicaleffectsandantivenomdosinginbrownsnakepseudonajasppenvenomingaustraliansnakebiteprojectasp14